Briumvi™ (ublituximab-xiiy) Intravenous Injection

Briumvi (ublituximab‑xiiy) is covered only for adults (≥18) with FDA‑approved relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing‑remitting MS, or active secondary progressive MS) and is excluded for patients <18, non‑relapsing forms (e.g., primary progressive MS), and non‑FDA uses. Coverage requires prescription by or consultation with a neurologist/MS specialist, adherence to the labeled dosing schedule (150 mg, then 450 mg at 2 weeks, then 450 mg every 24 weeks), 12‑month initial/renewal approvals, and for re‑authorization ≥12 months of prior Briumvi plus documentation of clinical benefit by objective measures or stabilization/improvement in specified symptoms.

"Relapsing forms of MS includes: relapsing-remitting disease."

Sign up to see full coverage criteria, indications, and limitations.